Capricor Therapeutics Faces FDA Review Extension Amid Securities Lawsuit
Capricor Therapeutics has received an extension from the FDA for its review of deramiocel, as an ongoing securities class action lawsuit proceeds with a lead plaintiff deadline.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) has been granted an extended review period by the U.S. Food and Drug Administration (FDA) for its drug candidate deramiocel. This regulatory development occurs as the company faces an ongoing securities class action lawsuit, with a crucial deadline for lead plaintiff appointment approaching.
The FDA's decision to extend the review timeline could impact the potential market entry of deramiocel. While specific reasons for the extension have not been detailed, it may indicate a need for further evaluation or data submission. Investors are also navigating the implications of the securities litigation.
The class action lawsuit alleges that Capricor made misleading statements to investors. Shareholders who purchased CAPR stock within a specified period must act by September 28, 2026, to be considered for appointment as lead plaintiff. Law firms specializing in securities litigation have been notifying affected investors of their rights and the impending deadline.
These concurrent events highlight the complexities and risks inherent in investing in biotechnology firms. The outcome of the FDA's review and the resolution of the legal challenges will be critical factors for the company's future performance and shareholder value.